TY - JOUR AB - Background: The dysregulation of glucose homeostasis via mental health stress is increasingly acknowledged, whereby depression independently increases the risk of the onset of type 2 diabetes by up to 60%. Contributing mental health factors starting in early life have further been considered, indicating that exposure to childhood emotional abuse is associated with both depression and an increased onset of type 2 diabetes in adulthood. However, the potential role of depression within the emotional abuse and type 2 diabetes link remains unknown. Methods: Data were derived from community-dwelling participants in southern and northeastern Germany who participated in the longitudinal KORA-F4 and SHIP-3 studies. Multivariable logistic regression analyses adjusted for lifestyle, somatic, and psychological risk factors were used to investigate the association between childhood emotional abuse, assessed retrospectively by the Childhood Trauma Screener, and newly diagnosed type 2 diabetes cases, which were confirmed using a standard oral glucose tolerance test. The mediating role of depressive symptoms between childhood emotional abuse and type 2 diabetes was assessed by the Patient Health Questionnaire-9 and calculated by using the Sobel test for mediation. Results: A total of 2,973 (53.2% women, 46.8% men) participants with a mean age of 49.7 were included in the analyses, of whom 5.9% (7.1% women, 4.5% men) reported emotional abuse in childhood. Participants exposed to childhood emotional abuse had a 1.70 (1.12-2.56; p = 0.02) times higher odds of depression in the fully adjusted model than unexposed participants. During the 6.5-year follow-up period, 104 (3.5%) participants developed type 2 diabetes. Participants who were exposed to childhood emotional abuse had a 2.56 (1.31-4.98, p = 0.005) times higher odds of developing type 2 diabetes than unexposed participants. This association was significantly mediated by the increased odds of depression in participants with childhood emotional abuse (Sobel Test, 1.84, p = 0.06; Goodman Test, 1.91, p = 0.05). Conclusion: The current results indicate that the increased likelihood of type 2 diabetes onset in participants who were exposed to childhood emotional abuse is significantly attributed to increased depression in adulthood. AU - Atasoy, S. AU - Johar, H. AU - Fleischer, T.* AU - Beutel, M.* AU - Binder, H.* AU - Braehler, E.* AU - Schomerus, G.* AU - Zöller, D.* AU - Kruse, J.* AU - Ladwig, K.H.* C1 - 64869 C2 - 52152 TI - Depression mediates the association between childhood emotional abuse and the onset of type 2 diabetes: Findings from German multi-cohort prospective studies. JO - Front. Psychiatr. VL - 13 PY - 2022 SN - 1664-0640 ER - TY - JOUR AB - The Federal Ministry of Education and Research (BMBF) issued a call for a new nationwide research network on mental disorders, the German Center of Mental Health (DZPG). The Munich/Augsburg consortium was selected to participate as one of six partner sites with its concept "Precision in Mental Health (PriMe): Understanding, predicting, and preventing chronicity." PriMe bundles interdisciplinary research from the Ludwig-Maximilians-University (LMU), Technical University of Munich (TUM), University of Augsburg (UniA), Helmholtz Center Munich (HMGU), and Max Planck Institute of Psychiatry (MPIP) and has a focus on schizophrenia (SZ), bipolar disorder (BPD), and major depressive disorder (MDD). PriMe takes a longitudinal perspective on these three disorders from the at-risk stage to the first-episode, relapsing, and chronic stages. These disorders pose a major health burden because in up to 50% of patients they cause untreatable residual symptoms, which lead to early social and vocational disability, comorbidities, and excess mortality. PriMe aims at reducing mortality on different levels, e.g., reducing death by psychiatric and somatic comorbidities, and will approach this goal by addressing interdisciplinary and cross-sector approaches across the lifespan. PriMe aims to add a precision medicine framework to the DZPG that will propel deeper understanding, more accurate prediction, and personalized prevention to prevent disease chronicity and mortality across mental illnesses. This framework is structured along the translational chain and will be used by PriMe to innovate the preventive and therapeutic management of SZ, BPD, and MDD from rural to urban areas and from patients in early disease stages to patients with long-term disease courses. Research will build on platforms that include one on model systems, one on the identification and validation of predictive markers, one on the development of novel multimodal treatments, one on the regulation and strengthening of the uptake and dissemination of personalized treatments, and finally one on testing of the clinical effectiveness, utility, and scalability of such personalized treatments. In accordance with the translational chain, PriMe's expertise includes the ability to integrate understanding of bio-behavioral processes based on innovative models, to translate this knowledge into clinical practice and to promote user participation in mental health research and care. AU - Falkai, P.* AU - Koutsouleris, N.* AU - Bertsch, K.* AU - Bialas, M.* AU - Binder, E.* AU - Bühner, M.* AU - Buyx, A.* AU - Cai, N. AU - Cappello, S.* AU - Ehring, T.* AU - Gensichen, J.* AU - Hamann, J.* AU - Hasan, A.* AU - Henningsen, P.* AU - Leucht, S.* AU - Möhrmann, K.H.* AU - Nagelstutz, E.* AU - Padberg, F.* AU - Peters, A. AU - Pfäffel, L.* AU - Reich-Erkelenz, D.* AU - Riedl, V.* AU - Rueckert, D.* AU - Schmitt, A.* AU - Schulte-Körne, G.* AU - Scheuring, E.* AU - Schulze, T.G.* AU - Starzengruber, R.* AU - Stier, S.* AU - Theis, F.J. AU - Winkelmann, J.* AU - Wurst, W. AU - Priller, J.* C1 - 64625 C2 - 52017 TI - Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health. JO - Front. Psychiatr. VL - 13 PY - 2022 SN - 1664-0640 ER - TY - JOUR AB - Introduction: The neuropeptide-Y (NPY) is involved in the development of alcoholism through NPY receptors. A T>C mutation causes substitution of leucine to proline at codon 7 (L7P; rs16139) in the signal peptide of neuropeptide Y is known to cause a 42% increase in plasma NPY levels. Studies that analyzed the association between NPY rs16139 and alcoholism risk did not demonstrate conclusive evidence for this relationship. The present study aims to evaluate the association between NPY gene rs16139 variant and alcohol dependence. Method: An electronic search of databases including PubMed and Google Scholar was performed to retrieve studies investigating the association between NPY rs16139 and alcoholism. The pooled odds ratio (OR) with 95% confidence interval (CI) was calculated in allelic and dominant genetic models. Sensitivity analyses and publication bias were assessed in our meta-analysis. The meta-analysis was conducted using the MetaGenyo web tool. Result: Significant heterogeneity was observed across studies (p < 0.001). Our results have shown that there is no significant association between NPY rs16139 variant and the risk of alcoholism in allelic (OR = 0.98, 95% CI 0.70–1.38, p = 0.921) and dominant models (OR = 0.98, 95% CI 0.69–1.40, p = 0.919). Begg's funnel plot and Egger's test have not shown publication bias (p = 0.332). Conclusion: To the best of our knowledge, this is the first meta-analysis that evaluates the relationship between the NPY rs16139 polymorphism and the risk of alcoholism. Our large-scale meta-analysis suggests that NPY rs16139 polymorphism is not associated with alcoholism. However, further studies are needed to increase our understanding of the relationship between NPY variants in alcoholism. AU - Chen, B.* AU - Yadav, M.* AU - Mulkalwar, M.* AU - Saikrishna, L.* AU - Verma, H.K. AU - Ye, W.* AU - Bhaskar, L.V.K.S.* C1 - 63525 C2 - 51578 CY - Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland TI - Meta-analysis on the association of neuropeptide Y rs16139 variant with the risk of alcoholism. JO - Front. Psychiatr. VL - 12 PB - Frontiers Media Sa PY - 2021 SN - 1664-0640 ER - TY - JOUR AB - Background: It is highly recommended that all patients with coronary artery disease should be screened for depression. The Major Depression Inventory (MDI) is a widely used self-rating scale for the assessment of depression but is not valid in Chinese language. The present study was designed to assess the reliability and validity of a version of the MDI translated into Chinese among patients with acute myocardial infarction (AMI). Methods: Data were derived from the "Multicenter Delay in Patients Experiencing Acute Myocardial Infarction in Shanghai" (MEDEA FAR-EAST) study. Using a cross-sectional study design, the Chinese version of the MDI was administered to a total of 267 inpatients. The internal consistency reliability of the MDI scale was evaluated based on the Cronbach's coefficient and the binary coefficient for the whole scale. Exploratory factor analysis was performed to assess the internal consistency of the MDI. To examine discriminant validity, we analyzed the correlation of the MDI score with the General Anxiety Disorder-7 (GAD-7) and World Health Organization-5 Well-Being Index (WHO-5) scale scores. Results: The Chinese version of the MDI showed high reliability (Cronbach's alpha = 0.909, split-half reliability = 0.866). We identified one factor that explained 52% of the variance, which indicated that the MDI has satisfactory structural validity. The correlations of the MDI scores with the GAD-7 scores (r = 0.425) and the WHO-5 scores (r = -0.365) were moderate, suggesting that the MDI has acceptable discriminant validity. Conclusions: The MDI was proved to be a highly reliable and satisfactory valid diagnostic screening tool to assess depression in Chinese cardiac patients. AU - Chen, Y.* AU - Fang, X. AU - Shuai, X.* AU - Fritzsche, K.* AU - Leonhart, R.* AU - Hoschar, S. AU - Li, L.* AU - Ladwig, K.-H. AU - Ma, W.* AU - Wu, H.* C1 - 56687 C2 - 47174 CY - Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland TI - Psychometric evaluation of the major depression inventory (MDI) as a depression severity scale in Chinese patients with coronary artery disease. Findings from the MEDEA FAR-EAST Study. JO - Front. Psychiatr. VL - 10 PB - Frontiers Media Sa PY - 2019 SN - 1664-0640 ER - TY - JOUR AB - The etiology of takotsubo cardiomyopathy (TTC)—a rare, reversible, and acquired form of cardiac diseases—is not yet fully explained. An exaggerated activation of the sympathetic-nervous-system (SNS) following stressful psychosocial life events is discussed to be of key importance. In this experimental study, we tested whether TTC patients, compared to heart-healthy controls, respond more strongly to supporting placebo interventions and stressful nocebo interventions targeting cardiac function. In a single experimental session, 20 female TTC patients and 20 age matched (mean age 61.5 years, ± 12.89) catheter-confirmed heart-healthy women were examined. Saline solution was administered three times i.v. to all participants, with the verbal suggestion they receive an inert substance with no effects on the heart (neutral condition), a drug that would support cardiac functions (positive condition), and a drug that would burden the heart (negative condition). Systolic and diastolic blood pressure (DBP/SBP), heart rate (HR), endocrine markers cortisol (µg/dl), copeptin (pmol/l), and subjective stress ratings (SUD) were assessed to examine alterations of the SNS and the hypothalamic–pituitary–adrenal axis (HPA). Before and after each intervention SUD was rated. One pre and three post serum cortisol and copeptin samples were assessed, and a long-term electrocardiogram as well as non-invasive, continuous blood pressure was recorded. The study design elucidated a significant increase of SUD levels as a response to the nocebo intervention, while perceived stress remained unaffected during the preceding neutral and positive interventions. Increasing SUD levels were accompanied by higher SBP and an anticipatory increase of HR shortly prior to the nocebo intervention. SBP increased also as a response to positive verbal suggestions (Bonferroni-corrected p-values >.05). Alterations of cortisol and copeptin due to the interventions and significant placebo effects failed to appear. Interestingly no differences between TCC patients and controls could be found.These findings do not support the assumption of an exaggerated activation of the SNS as a discriminatory factor for TTC. Since especially the nocebo intervention revealed negative subjective and objective effects, our results underscore the urgent need to consider carefully the impact of verbal suggestions in the interaction with cardiac patients in daily clinical routine. This study is registered at the Deutsches Register Klinischer Studien (DRKS00009296). AU - Olliges, E.* AU - Schneider, S.* AU - Schmidt, G.* AU - Sinnecker, D.* AU - Müller, A.* AU - Burgdorf, C.* AU - Braun, S.* AU - Holdenrieder, S.* AU - Ebell, H.* AU - Ladwig, K.-H. AU - Meissner, K.* AU - Ronel, J.* C1 - 56772 C2 - 47347 TI - Placebo and nocebo effects in patients with takotsubo cardiomyopathy and heart-healthy controls. JO - Front. Psychiatr. VL - 10 PY - 2019 SN - 1664-0640 ER - TY - JOUR AB - Objective: Patients' expectations about the benefit of an intervention are important determinants of the placebo effect. Little is known about the extent to which expectations influence outcomes of treatments in the field of appetite regulation. This study aimed to investigate the effects of treatment-related expectations on subjective and objective markers of appetite.Methods: 90 healthy participants of normal weight were randomly allocated to either an appetite-enhancing placebo group, a satiety-enhancing placebo group, or a control group. All participants received a placebo capsule along with group-specific verbal suggestions to either be appetite-promoting, or satiety-enhancing, or to have no effect on appetite. Before and during the 2 h following randomization, participants were repeatedly asked to rate feelings of hunger and satiety on visual analog scales (VAS), and blood samples were taken repeatedly to assess plasma ghrelin levels as a physiological marker of hunger.Results: In comparison to the control group, the satiety-enhancing placebo intervention significantly reduced appetite and increased satiety. The appetite-enhancing placebo intervention did not alter subjective levels of hunger, but increased plasma ghrelin levels in females.Conclusions: Results provide the first experimental evidence that appetite-regulating placebo interventions can elicit a psychobiological response. Expectations are important factors to consider when evaluating the effects of interventions in the field of appetite regulation. AU - Hoffmann, V.* AU - Lanz, M.* AU - Mackert, J.* AU - Müller, T.D. AU - Tschöp, M.H. AU - Meissner, K.* C1 - 55079 C2 - 46036 CY - Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland TI - Effects of placebo interventions on subjective and objective markers of appetite-a randomized controlled trial. JO - Front. Psychiatr. VL - 9 PB - Frontiers Media Sa PY - 2018 SN - 1664-0640 ER -